Table 1 Demographic and clinical characteristics of patients with neuropathy and FGFR3 antibodies

Demographics

Age (years)

51.9 years (IQR 48–57)

Female gender

9 (64.3%)

Duration of symptoms (years)

1.95 (IQR 0.75–2.0)

Onset

Acute (≤ 4 weeks)

3 (21.4%)

Subacute (4–12 weeks)

3 (21.4%)

Chronic (≥12 weeks)

8 (57.1%)

Initial clinical manifestations

Painful paresthesia

14 (100%)

Gait instability

6 (42.9%)

Autonomic symptoms

4 (28.6%)

Constitutional symptoms (weight loss, fatigue)

6 (42.9%)

Autonomic symptoms

Orthostatic hypotension

2 (14.3%)

Neurogenic bladder

2 (14.3%)

Sensory exam findings

Distal sensory loss to pin prick in hands only

3 (21.4%)

Distal sensory loss to pin prick in feet only

8 (57.1%)

Distal sensory loss to pin prick in hands and feet

3 (21.4%)

Impaired vibration sensation in distal extremities

11 (78.6%)

Impaired proprioception in distal extremities

5 (35.7%)

Reflexes

Reduced or absent lower limb DTRs

8 (57.1%)

Reduced or absent upper limb DTRs

2 (14.3%)

Reduced or absent upper and lower limb DTRs

1 (7.1%)

Motor exam findings

Distal upper-extremity weakness (mild)

1 (7.1%)

Distal lower-extremity weakness (mild)

6 (42.9%)

No motor weakness

7 (50.0%)

Co-existing conditions

Trigeminal neuralgia

3 (21.4%)

Diabetes mellitus type 1

1 (7.1%)

Grave’s disease

1 (7.1%)

Rheumatoid arthritis

1 (7.1%)

Renal cell carcinoma

1 (7.1%)